Renaissance Technologies
ZNTL icon

Renaissance Technologies’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Renaissance Technologies’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.8M Sell
1,609,078
-329,067
-17% -$1.31M 0.01% 1191
2026
Q1 		$4.54M Sell
1,938,145
-945,600
-33% -$2.44M 0.01% 1435
2025
Q4 		$3.89M Buy
2,883,745
+558,390
+24% +$813K 0.01% 1456
2025
Q3 		$3.51M Buy
2,325,355
+795,802
+52% +$1.19M ﹤0.01% 1693
2025
Q2 		$1.77M Buy
1,529,553
+703,512
+85% +$928K ﹤0.01% 2187
2025
Q1 		$1.31M Buy
826,041
+286,696
+53% +$618K ﹤0.01% 2238
2024
Q4 		$1.63M Sell
539,345
-17,599
-3% -$57.7K ﹤0.01% 2179
2024
Q3 		$2.05M Sell
556,944
-104,738
-16% -$381K ﹤0.01% 2002
2024
Q2 		$2.71M Buy
661,682
+399,745
+153% +$4.46M ﹤0.01% 1685
2024
Q1 		$4.13M Sell
261,937
-47,340
-15% -$651K 0.01% 1535
2023
Q4 		$4.69M Buy
309,277
+23,840
+8% +$348K 0.01% 1392
2023
Q3 		$5.73M Buy
285,437
+75,000
+36% +$1.9M 0.01% 1225
2023
Q2 		$5.94M Buy
210,437
+177,700
+543% +$4.26M 0.01% 1332
2023
Q1 		$563K Buy
+32,737
New +$663K ﹤0.01% 2819
2022
Q2 		– Sell
-109,337
Closed -$5.04M – 4631
2022
Q1 		$5.04M Buy
+109,337
New +$5.9M 0.01% 1585
2021
Q4 		– Sell
-31,337
Closed -$2.09M – 4277
2021
Q3 		$2.09M Buy
+31,337
New +$1.81M ﹤0.01% 2052
2021
Q1 		– Sell
-6,397
Closed -$332K – 3774
2020
Q4 		$332K Buy
+6,397
New +$289K ﹤0.01% 2995

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Renaissance Technologies's ZNTL Position: Q2 2026 in Review

Renaissance Technologies reduced its Zentalis Pharmaceuticals (ZNTL) stake by 17% in Q2 2026, selling an estimated $1.31M and leaving 1,609,078 shares worth $7.8M. The position accounts for 0.01% of the portfolio, ranked #1191.

Renaissance Technologies first reported a position in ZNTL in Q4 2020 and has held it in 17 quarters since. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Renaissance Technologies held 1,609,078 shares of Zentalis Pharmaceuticals worth $7.8M as of Q2 2026.
  • Renaissance Technologies sold 329,067 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $1.31M.
  • Zentalis Pharmaceuticals made up 0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1191 holding.
  • Renaissance Technologies first reported a position in Zentalis Pharmaceuticals in Q4 2020 and has held it in 17 quarters since.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.